お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
995303

抗肥満治療の世界市場:市場調査、予測(~2026年)、COVID-19の累積的な影響

Anti-Obesity Therapeutics Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
抗肥満治療の世界市場:市場調査、予測(~2026年)、COVID-19の累積的な影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗肥満治療の市場規模は、2020年の78億9,845万米ドルから、2025年末までに112億9,281万米ドルに成長すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮した、COVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

 

当レポートでは抗肥満治療の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画の作成
    • 実行:調査の実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場の見通し
  • 地域の見通し
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 南北アメリカ

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第7章 アジア太平洋地域

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第8章 欧州、中東・アフリカ

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第9章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第10章 企業のユーザビリティプロファイル

  • Alizyme
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Eisai Company
  • GlaxoSmithKline PLC
  • Norgine Pharmaceuticals Ltd
  • Novo Nordisk
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Vivus
  • Zafgen

第11章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 5. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 6. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 7. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 8. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 9. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 10. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 11. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 13. CALIFORNIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 14. FLORIDA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 15. ILLINOIS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 16. NEW YORK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 17. OHIO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 18. PENNSYLVANIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. TEXAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 23. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 34. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SCORES
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: RANKING
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET: CONTACT DETAILS
目次
Product Code: MRR-EC2E133E33FA

The Global Anti-Obesity Therapeutics Market size was estimated at USD 7,898.44 Million in 2020 and expected to reach USD 8,523.36 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.25% to reach USD 12,709.09 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anti-Obesity Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Geography, the Anti-Obesity Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Obesity Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Obesity Therapeutics Market, including Alizyme, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eisai Company, GlaxoSmithKline PLC, Norgine Pharmaceuticals Ltd, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Vivus, and Zafgen.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anti-Obesity Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Obesity Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Obesity Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anti-Obesity Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anti-Obesity Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Anti-Obesity Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anti-Obesity Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Geography Outlook
  • 3.4. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder globally
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
      • 5.1.2.2. Negative perception about the anti-obesity therapeutics among the health professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
      • 5.1.3.3. Strategic collaboration by the pharma companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of knowledge regarding weight management
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Americas Anti-Obesity Therapeutics Market

  • 6.1. Introduction
  • 6.2. Argentina
  • 6.3. Brazil
  • 6.4. Canada
  • 6.5. Mexico
  • 6.6. United States
    • 6.6.1. California
    • 6.6.2. Florida
    • 6.6.3. Illinois
    • 6.6.4. New York
    • 6.6.5. Ohio
    • 6.6.6. Pennsylvania
    • 6.6.7. Texas

7. Asia-Pacific Anti-Obesity Therapeutics Market

  • 7.1. Introduction
  • 7.2. China
  • 7.3. India
  • 7.4. Indonesia
  • 7.5. Japan
  • 7.6. Malaysia
  • 7.7. Philippines
  • 7.8. South Korea
  • 7.9. Thailand

8. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. France
  • 8.3. Germany
  • 8.4. Italy
  • 8.5. Netherlands
  • 8.6. Qatar
  • 8.7. Russia
  • 8.8. Saudi Arabia
  • 8.9. South Africa
  • 8.10. Spain
  • 8.11. United Arab Emirates
  • 8.12. United Kingdom

9. Competitive Landscape

  • 9.1. FPNV Positioning Matrix
    • 9.1.1. Quadrants
    • 9.1.2. Business Strategy
    • 9.1.3. Product Satisfaction
  • 9.2. Market Ranking Analysis
  • 9.3. Market Share Analysis, By Quadrant
  • 9.4. Market Share Analysis, By Company
  • 9.5. Competitive Scenario
    • 9.5.1. Merger & Acquisition
    • 9.5.2. Agreement, Collaboration, & Partnership
    • 9.5.3. New Product Launch & Enhancement
    • 9.5.4. Investment & Funding
    • 9.5.5. Award, Recognition, & Expansion

10. Company Usability Profiles

  • 10.1. Alizyme
  • 10.2. Boehringer Ingelheim GmbH
  • 10.3. Bristol-Myers Squibb
  • 10.4. Eisai Company
  • 10.5. GlaxoSmithKline PLC
  • 10.6. Norgine Pharmaceuticals Ltd
  • 10.7. Novo Nordisk
  • 10.8. Pfizer
  • 10.9. Rhythm Pharmaceuticals
  • 10.10. Shionogi USA
  • 10.11. Takeda Pharmaceutical
  • 10.12. Vivus
  • 10.13. Zafgen

11. Appendix

  • 11.1. Discussion Guide
  • 11.2. License & Pricing
  • 11.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.